Previous close | 3.4000 |
Open | 3.3000 |
Bid | 4.0000 |
Ask | 5.4000 |
Strike | 35.00 |
Expiry date | 2026-01-16 |
Day's range | 3.4000 - 3.4000 |
Contract range | N/A |
Volume | |
Open interest | 61 |
Syros Pharmaceuticals (SYRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that 14 abstracts, 11 of which are oral presentations, will be presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held May 5 - 9 in Seattle. The data continue to reinforce the robust efficacy and safety profile of SYFOVRE® (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). “The 11 oral
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.